ValuEngine cut shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a sell rating in a report released on Monday.
ENDP has been the subject of a number of other research reports. JMP Securities downgraded shares of Endo International from an outperform rating to a market perform rating in a report on Monday, February 26th. Leerink Swann started coverage on shares of Endo International in a report on Tuesday, January 2nd. They issued an outperform rating and a $12.00 price objective for the company. Mizuho reiterated a buy rating and issued a $12.00 price objective (down previously from $14.00) on shares of Endo International in a report on Wednesday, January 3rd. Canaccord Genuity set a $7.00 price objective on shares of Endo International and gave the company a hold rating in a report on Wednesday, February 21st. Finally, Vetr downgraded shares of Endo International from a strong-buy rating to a buy rating and set a $8.92 price objective for the company. in a report on Monday, December 18th. Four investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Endo International has a consensus rating of Hold and a consensus target price of $9.40.
ENDP stock traded down $0.20 during mid-day trading on Monday, reaching $5.52. The company’s stock had a trading volume of 1,479,762 shares, compared to its average volume of 5,751,781. The company has a market cap of $1,244.01, a price-to-earnings ratio of 1.44 and a beta of 0.38. The company has a current ratio of 1.02, a quick ratio of 0.85 and a debt-to-equity ratio of 17.00. Endo International has a fifty-two week low of $5.27 and a fifty-two week high of $14.15.
Several hedge funds and other institutional investors have recently made changes to their positions in ENDP. Cornerstone Capital Management Holdings LLC. increased its holdings in shares of Endo International by 64.0% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 135,627 shares of the company’s stock worth $1,160,000 after buying an additional 52,927 shares during the last quarter. Nisa Investment Advisors LLC purchased a new position in shares of Endo International during the 4th quarter worth approximately $236,000. Oakbrook Investments LLC purchased a new position in shares of Endo International during the 4th quarter worth approximately $133,000. Alps Advisors Inc. boosted its position in shares of Endo International by 22.9% during the 4th quarter. Alps Advisors Inc. now owns 307,839 shares of the company’s stock worth $2,386,000 after purchasing an additional 57,328 shares during the period. Finally, River & Mercantile Asset Management LLP boosted its position in shares of Endo International by 32.7% during the 4th quarter. River & Mercantile Asset Management LLP now owns 475,650 shares of the company’s stock worth $3,679,000 after purchasing an additional 117,110 shares during the period. Institutional investors and hedge funds own 94.72% of the company’s stock.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.